Automation Deployed to Contain Cost of Goods Sold and Vector Manufacturing Standardization Will Create New Growth Opportunities
The cell and gene therapy segment is one of the fastest growing segments in the biopharmaceutical space. While the science behind the therapy has grown by leaps and bounds on the back of decades worth of research, manufacturing has unfortunately lagged behind.
To fully harness the curative potential of these therapies and ensure greater reach and affordability to patients, it is imperative that aggressive investments in manufacturing technology and capacity are made today. Investments in manufacturing technology advancements including automation, single-use technologies, and GMP-in-a-box, will not only enable operational efficiency gains but also reduce project costs, generating benefits which can be transferred directly to the patients.
A large part of this growth in the cell and gene therapy product pipeline is being driven by small and mid-sized biotechs that depend on CDMOs to mitigate product development risks and diffuse infrastructure investments to be able to build future products pipeline.
This research service focuses on the critical role being played by CDMOs in not only supporting new product research and development but also in creating standardized manufacturing protocols. Additionally, the study explores different cross-sections of the market and discusses market dynamics for autologous and allogeneic solutions for cell and gene therapies and for products being manufactured for clinical trial use and for commercial markets. The variability in market dynamics, manufacturing protocols, and business models across cross-sections is high. Therefore, the study also covers the emergence of non-traditional CDMOs that have thrived as a result of this variability.
The study also provides a comprehensive and critical analysis of nationally coordinated efforts towards infrastructure development and the rise of academic institutes and hospitals in meeting not only the demand from clinics, but also the demand of the commercial market. The study also analyses the growth of specialist CDMOs focusing on vectors and plasmids, for instance. The captures the regional outlook for growth based on the currently installed capacities as well as the pipeline investments being made towards expansion. Lastly, the study tracks growth opportunities across the entire product development spectrum from supply chain to upstream and downstream manufacturing.
Table of Contents
- Why Is It Increasingly Difficult to Grow?
- The Strategic Imperative 8™
- The Impact of the Top Three Strategic Imperatives on CDMO Industry
- Growth Opportunities Fuel the Growth Pipeline Engine™
- Scope of Analysis
- Segmentation (Product Groups)
- Segmentation (Source of Starting Material)
- Outsourcing Dynamics
- Key Competitors
- Vendor Landscape
- Market Engineering Measurements
- Growth Drivers
- Growth Restraints
- Forecast Assumptions
- Revenue Forecast
- Revenue Forecast Discussion
- Revenue Forecast by Product Group
- Revenue Forecast Analysis by Segment
- Revenue Forecast by Stage of Development
- Revenue Forecast Analysis by Region and Development Stage
- Competitive Environment
- CDMO Categorization: Primed for Business Model Disruption
- Growth Opportunity Universe Summary
- Growth Opportunity 1: Traceability-enabled Supply Chain for Autologous Therapies, 2020
- Need for Investment in Supply Chain
- Companies to Action
- Growth Opportunity 2: Standardization of Viral Vector Manufacturing, 2020
- Demand for Viral Vector by Vector Types
- Future of Vector Manufacturing
- Growth Opportunity 3: Donor-sampling and Cell-banking for Allogeneic Stem Cell Therapies, 2020
- Cell-banking Ecosystem
- Growth Opportunity 4: Factory-in-a-box Model for Decentralized Manufacturing, 2020
- Advantages of Factory-in-a-box
- Comparative Analysis of Different Models
- Companies to Action
- Growth Opportunity 5: CGT Development and Manufacturing in China, 2020
- Cell and Gene Landscape in China